Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. reported fiscal year 2025 revenue of $1.01 billion, generating a gross profit of $546.0 million. However, the company recorded significant operating expenses totaling $733.3 million, including $445.0 million in selling, general and administrative costs, $193.1 million in research and development, $75.2 million in acquired in-process research and development expenses, and $20.0 million in litigation and settlement expenses. This resulted in an operating loss of $187.3 million and a net loss of $204.7 million. The company ended the year with $881.1 million in total assets, including $618.1 million in current assets, but carried $725.9 million in total liabilities, resulting in stockholders' equity of $155.2 million. Cash flow from operations was negative $9.7 million, though investing activities generated positive cash flow of $72.9 million primarily from maturities of short-term investments.

Key Takeaways